GlassScriptPhysician profile
Meredith H Mckee
NPI 1891967360
$6,551.75
in general payments reported to CMS, 2019-2025
27 companies · $1,422 in 2025
The $1,422 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,128 · 2022: $1,109 · 2023: $1,397 · 2024: $1,495 · 2025: $1,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,314.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,655.93 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $1,490.18 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $734.00 | 2021-2025 | |
| Lilly USA, LLC | $622.79 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.82 | 2021-2025 | Jardiance, Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $258.82 | 2022-2025 | |
| Pfizer INC. | $256.95 | 2021-2025 | |
| Abbott Laboratories | $175.47 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $172.08 | 2022-2023 | Quviviq |
| Amarin Pharma, INC. | $136.16 | 2021-2022 | |
| Glaxosmithkline, LLC. | $116.54 | 2021-2025 | Arexvy, Penmenvy, Shingrix |
| Merck Sharp & Dohme LLC | $100.40 | 2021-2024 | Capvaxive, Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $80.24 | 2022-2025 | Trintellix |
| Phathom Pharmaceuticals, INC. | $57.73 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $47.71 | 2024 | Injectafer |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $37.84 | 2022 | |
| Astellas Pharma US INC | $36.12 | 2021 | |
| Sumitomo Pharma America, INC. | $34.87 | 2023-2024 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.82 | 2023-2025 | Xifaxan, Trulance |
| Amgen INC. | $32.66 | 2023-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $31.25 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $31.16 | 2021 | |
| Edwards Lifesciences Corporation | $24.68 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Seqirus USA INC | $23.40 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Xeris Pharmaceuticals, INC. | $20.99 | 2022 | |
| Esperion Therapeutics, INC. | $13.72 | 2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $11.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Mckee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.